Cargando…

The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is characterised by the progressive deposition of excessive extracellular matrix proteins within the lung parenchyma and represents the most rapidly progressive and fatal of all fibrotic conditions. Current anti-fibrotic drugs approved for the treatment of IPF fai...

Descripción completa

Detalles Bibliográficos
Autores principales: Platé, Manuela, Guillotin, Delphine, Chambers, Rachel C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488186/
https://www.ncbi.nlm.nih.gov/pubmed/33060168
http://dx.doi.org/10.1183/16000617.0269-2020
_version_ 1784792605009117184
author Platé, Manuela
Guillotin, Delphine
Chambers, Rachel C
author_facet Platé, Manuela
Guillotin, Delphine
Chambers, Rachel C
author_sort Platé, Manuela
collection PubMed
description Idiopathic pulmonary fibrosis (IPF) is characterised by the progressive deposition of excessive extracellular matrix proteins within the lung parenchyma and represents the most rapidly progressive and fatal of all fibrotic conditions. Current anti-fibrotic drugs approved for the treatment of IPF fail to halt disease progression and have significant side-effect profiles. Therefore, there remains a pressing need to develop novel therapeutic strategies for IPF. Mammalian target of rapamycin (mTOR) forms the catalytic subunit of two complexes, mTORC1 and mTORC2. mTORC1 acts as critical cellular sensor which integrates intracellular and extracellular signals to reciprocally regulate a variety of anabolic and catabolic processes. The emerging evidence for a critical role for mTORC1 in influencing extracellular matrix production, metabolism, autophagy and senescence in the setting of IPF highlights this axis as a novel therapeutic target with the potential to impact multiple IPF pathomechanisms.
format Online
Article
Text
id pubmed-9488186
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-94881862022-11-14 The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis Platé, Manuela Guillotin, Delphine Chambers, Rachel C Eur Respir Rev Mini Review Idiopathic pulmonary fibrosis (IPF) is characterised by the progressive deposition of excessive extracellular matrix proteins within the lung parenchyma and represents the most rapidly progressive and fatal of all fibrotic conditions. Current anti-fibrotic drugs approved for the treatment of IPF fail to halt disease progression and have significant side-effect profiles. Therefore, there remains a pressing need to develop novel therapeutic strategies for IPF. Mammalian target of rapamycin (mTOR) forms the catalytic subunit of two complexes, mTORC1 and mTORC2. mTORC1 acts as critical cellular sensor which integrates intracellular and extracellular signals to reciprocally regulate a variety of anabolic and catabolic processes. The emerging evidence for a critical role for mTORC1 in influencing extracellular matrix production, metabolism, autophagy and senescence in the setting of IPF highlights this axis as a novel therapeutic target with the potential to impact multiple IPF pathomechanisms. European Respiratory Society 2020-10-15 /pmc/articles/PMC9488186/ /pubmed/33060168 http://dx.doi.org/10.1183/16000617.0269-2020 Text en Copyright ©ERS 2020. https://creativecommons.org/licenses/by-nc/4.0/This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
spellingShingle Mini Review
Platé, Manuela
Guillotin, Delphine
Chambers, Rachel C
The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis
title The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis
title_full The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis
title_fullStr The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis
title_full_unstemmed The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis
title_short The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis
title_sort promise of mtor as a therapeutic target pathway in idiopathic pulmonary fibrosis
topic Mini Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488186/
https://www.ncbi.nlm.nih.gov/pubmed/33060168
http://dx.doi.org/10.1183/16000617.0269-2020
work_keys_str_mv AT platemanuela thepromiseofmtorasatherapeutictargetpathwayinidiopathicpulmonaryfibrosis
AT guillotindelphine thepromiseofmtorasatherapeutictargetpathwayinidiopathicpulmonaryfibrosis
AT chambersrachelc thepromiseofmtorasatherapeutictargetpathwayinidiopathicpulmonaryfibrosis
AT platemanuela promiseofmtorasatherapeutictargetpathwayinidiopathicpulmonaryfibrosis
AT guillotindelphine promiseofmtorasatherapeutictargetpathwayinidiopathicpulmonaryfibrosis
AT chambersrachelc promiseofmtorasatherapeutictargetpathwayinidiopathicpulmonaryfibrosis